These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 1721271

  • 21. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation.
    Fries D, Rucay P, Samuel D, Hiesse C, Meduri G, Callard P, Fredj G, Bismuth H.
    Transplant Proc; 1991 Dec; 23(6):3099-100. PubMed ID: 1721370
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation.
    Winkler M, Pichlmayr R, Neuhaus P, McMaster P, Calne R, Otto G, Williams R, Bismuth H, Groth C.
    Transpl Int; 1994 Dec; 7 Suppl 1():S58-63. PubMed ID: 11271312
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Neurotoxicity of FK 506 in liver transplant recipients.
    Frank B, Perdrizet GA, White HM, Marsh JW, Lemann W, Woodle ES.
    Transplant Proc; 1993 Apr; 25(2):1887-8. PubMed ID: 7682355
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients.
    Hebert MF, Ascher NL, Lake JR, Roberts JP.
    Transplant Proc; 1991 Dec; 23(6):3109-10. PubMed ID: 1721373
    [No Abstract] [Full Text] [Related]

  • 28. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
    Sher LS, Cosenza CA, Petrovic LM, Rojter S, Hoffman A, Lopez RR, Meehan M, Pan SH, Vierling J, Makowka L.
    Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
    Mueller AR, Platz KP, Bechstein WO, Blumhardt G, Lobeck H, Hop U, Neuhaus P.
    Transplant Proc; 1994 Dec; 26(6):3637-9. PubMed ID: 7527984
    [No Abstract] [Full Text] [Related]

  • 31. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
    Song GW, Lee SG, Hwang S, Kim KH, Kim WJ, Sin MH, Yoon YI, Tak EY.
    Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
    [Abstract] [Full Text] [Related]

  • 32. Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group.
    Wiesner RH.
    Transplant Proc; 1998 Jun; 30(4):1399-400. PubMed ID: 9636565
    [No Abstract] [Full Text] [Related]

  • 33. Long-term insulin requirement after liver transplantation with FK 506 in American veterans.
    Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):677-8. PubMed ID: 7679839
    [No Abstract] [Full Text] [Related]

  • 34. FK 506 treatment of intractable rejection after liver transplantation.
    Jost U, Winkler M, Ringe B, Rodeck B, Pichlmayr R.
    Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
    [No Abstract] [Full Text] [Related]

  • 35. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.
    Porayko MK, Textor SC, Krom RA, Hay JE, Gores GJ, Richards TM, Crotty PH, Beaver SJ, Steers JL, Wiesner RH.
    Mayo Clin Proc; 1994 Feb; 69(2):105-11. PubMed ID: 7508536
    [Abstract] [Full Text] [Related]

  • 36. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.
    U.S. Multicenter FK506 Liver Study Group.
    N Engl J Med; 1994 Oct 27; 331(17):1110-5. PubMed ID: 7523946
    [Abstract] [Full Text] [Related]

  • 37. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients.
    Jindal RM, Popescu I, Schwartz ME, Emre S, Boccagni P, Miller CM.
    Transplantation; 1994 Aug 15; 58(3):370-2. PubMed ID: 7519799
    [No Abstract] [Full Text] [Related]

  • 38. FK 506 rescue therapy for refractory acute rejection in five liver recipients.
    Rucay P, Samuel D, Gillet D, Bismuth H.
    Transplant Proc; 1991 Dec 15; 23(6):3000-1. PubMed ID: 1721340
    [No Abstract] [Full Text] [Related]

  • 39. Effects of intrahepatic arterial and intraportal administration of FK 506 on liver allograft survival in rats.
    Yano K, Fukuda Y, Sumimoto R, Ito H, Sumimoto K, Dohi K.
    Transpl Int; 1994 Dec 15; 7 Suppl 1():S187-93. PubMed ID: 11271200
    [Abstract] [Full Text] [Related]

  • 40. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
    Arnold JC, Theilmann L.
    Z Gastroenterol; 1995 Oct 15; 33(10):624-5. PubMed ID: 7502559
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.